Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/annrheumdis-2017-212268 http://scihub22266oqcxt.onion/10.1136/annrheumdis-2017-212268 C5867400!5867400!29275334     free     free     free Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 231.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 265.2 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 298.79999999999995 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Ann+Rheum+Dis 2018 ; 77 (3): 412-6 Nephropedia Template TP {{tp|p=29275334|t=2018. Effect of rituximab on a salivary gland ultrasound score in primary Sjögren?s syndrome: results of the TRACTISS randomised double-blind multicentre substudy |pdf=|usr=}}{{29275334}} gab.com Text Effect of rituximab on a salivary gland ultrasound score in primary Sjögren s syndrome: results of the TRACTISS randomised double-blind multicentre substudy JO: Ann Rheum Dis http://www.kidney.de/pget.php?&tw=1&pmid=29275334 #FOAvip Objectives: To compare the effects of rituximab versus placebo on salivary gland ultrasound (SGUS) in primary Sjögren?s syndrome (PSS) in a multicentre, multiobserver phase III trial substudy. Methods: Subjects consenting to SGUS were randomised to rituximab or placebo given at weeks 0, 2, 24 and 26, and scanned at baseline and weeks 16 and 48. Sonographers completed a 0?11 total ultrasound score (TUS) comprising domains of echogenicity, homogeneity, glandular definition, glands involved and hypoechoic foci size. Baseline-adjusted TUS values were analysed over time, modelling change from baseline at each time point. For each TUS domain, we fitted a repeated-measures logistic regression model to model the odds of a response in the rituximab arm (?1-point improvement) as a function of the baseline score, age category, disease duration and time point. Results: 52 patients (n=26?rituximab and n=26?placebo) from nine centres completed baseline and one or more follow-up visits. Estimated between-group differences (rituximab-placebo) in baseline-adjusted TUS were ?1.2 (95% CI ?2.1 to ?0.3; P=0.0099) and ?1.2 (95% CI ?2.0 to ?0.5; P=0.0023) at weeks 16 and 48. Glandular definition improved in the rituximab arm with an OR of 6.8 (95% CI 1.1 to 43.0; P=0.043) at week 16 and 10.3 (95% CI 1.0 to 105.9; P=0.050) at week 48. Conclusions: We demonstrated statistically significant improvement in TUS after rituximab compared with placebo. This encourages further research into both B cell depletion therapies in PSS and SGUS as an imaging biomarker. Trial registration number: 65360827, 2010-021430-64; Results. Twit Text FOAVip Effect of rituximab on a salivary gland ultrasound score in primary Sjögren s syndrome: results of the TRACTISS randomised double-blind multicentre substudy ????Ann Rheum Dis http://www.kidney.de/pget.php?&tw=1&pmid=29275334 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=29275334 #FOAvip English Wikipedia <ref>{{Cite pmid|29275334}}</ref> Effect of rituximab on a salivary gland ultrasound score in primary Sjögren?s syndrome: results of the TRACTISS randomised double-blind multicentre substudy #MMPMID29275334 Fisher BA; Everett CC; Rout J; O?Dwyer JL; Emery P; Pitzalis C; Ng WF; Carr A; Pease CT; Price EJ; Sutcliffe N; Makdissi J; Tappuni AR; Gendi NST; Hall FC; Ruddock SP; Fernandez C; Hulme CT; Davies KA; Edwards CJ; Lanyon PC; Moots RJ; Roussou E; Richards A; Sharples LD; Bombardieri M; Bowman SJ Ann Rheum Dis 2018[Mar]; 77 (3): 412-6 PMID29275334show ga Objectives: To compare the effects of rituximab versus placebo on salivary gland ultrasound (SGUS) in primary Sjögren?s syndrome (PSS) in a multicentre, multiobserver phase III trial substudy. Methods: Subjects consenting to SGUS were randomised to rituximab or placebo given at weeks 0, 2, 24 and 26, and scanned at baseline and weeks 16 and 48. Sonographers completed a 0?11 total ultrasound score (TUS) comprising domains of echogenicity, homogeneity, glandular definition, glands involved and hypoechoic foci size. Baseline-adjusted TUS values were analysed over time, modelling change from baseline at each time point. For each TUS domain, we fitted a repeated-measures logistic regression model to model the odds of a response in the rituximab arm (?1-point improvement) as a function of the baseline score, age category, disease duration and time point. Results: 52 patients (n=26?rituximab and n=26?placebo) from nine centres completed baseline and one or more follow-up visits. Estimated between-group differences (rituximab-placebo) in baseline-adjusted TUS were ?1.2 (95% CI ?2.1 to ?0.3; P=0.0099) and ?1.2 (95% CI ?2.0 to ?0.5; P=0.0023) at weeks 16 and 48. Glandular definition improved in the rituximab arm with an OR of 6.8 (95% CI 1.1 to 43.0; P=0.043) at week 16 and 10.3 (95% CI 1.0 to 105.9; P=0.050) at week 48. Conclusions: We demonstrated statistically significant improvement in TUS after rituximab compared with placebo. This encourages further research into both B cell depletion therapies in PSS and SGUS as an imaging biomarker. Trial registration number: 65360827, 2010-021430-64; Results. äEffect of rituximab on a salivary gland ultrasound score in primary Sj(epmc).pdf DeepDyve Pubget Overpricing